H.C. Wainwright reiterates Madrigal Pharmaceuticals stock rating citing market position

H.C. Wainwright reiterated a Buy rating and $620 price target for Madrigal Pharmaceuticals (MDGL), citing its market position and undervaluation. The company reported strong Q3 2026 results, including $431.3M revenue and $1.83 EPS, exceeding expectations. MDGL's gross profit margin is 90.96%, with 93% revenue growth over the last year.

Original reporting
Published Nov 12, 2026, 11:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MDGL
Bullish
medium confidence
Mentioned
$MDGL
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MDGLBullishLow
01

Why it matters

Limited impact; the reiteration reinforces existing sentiment but adds no fresh catalyst.

02

Market read

The piece is a recap of prior earnings and analyst opinion, offering little new trading insight.

03

What to watch

No new clinical data or earnings surprise accompanies the rating.

Relevance 4/10Novelty 2/10Timing: none

Background

The article repeats an analyst's prior Buy rating and price target for MDGL, citing past earnings that were released nine days earlier.

Company-level read

Ticker impact

$MDGLBullishMedium confidence
Context

H.C. Wainwright reiterated a Buy rating and raised the price target to $620 for Madrigal Pharmaceuticals.

Expected impact

potential upward pressure as investors price in the higher target.

Evidence & confidence

The rating change is a repeat of a prior view and does not introduce new fundamentals; impact is limited to sentiment.

Market effects

Minimal; the MASH therapy market remains unchanged.

None

Low

Counterpoint

The reiteration may be seen as overoptimistic given the modest recent price movement.

Key entities

  • Madrigal Pharmaceuticals

    Biopharma focused on MASH therapy.

  • H.C. Wainwright

    Equity research provider issuing the rating.

Related articles

$MDGLMed

Madrigal reports real-world data on liver disease drug Rezdiffra

Madrigal Pharmaceuticals (MDGL) presented real-world data on its liver disease drug Rezdiffra at a liver disease conference. Studies showed 37% to 55% of patients achieved at least 25% improvement in liver stiffness after a year, with 83% to 93% improving or stabilizing. Safety findings were consistent with clinical trials. Rezdiffra is approved for treating adults with MASH.

$MDGLMedAI 8/10

Madrigal (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 net sales of $431M, up 50% YoY, driven by demand for Rezdiffra. The company had 55,850 active Rezdiffra patients, nearly double the previous year. Madrigal expects the U.S. F2/F3 MASH market to grow 30% by year-end, with Rezdiffra penetrating about 1% of the total opportunity.